-
admin
Posts
Recurrent Energy Closes $103 Million Tax Credit Transfer Agreement with Bank of America for North Fork Solar Project
The 160 MW North Fork Solar Project is now in operation, supplying power to the Oklahoma Municipal Power Authority GUELPH, ON, June 27, 2024 /PRNewswire/...
Odaseva Raises $54M Series C Round to Expand Product Offerings and Continue Category Leadership
Latest funding round capitalizes on recent growth, catalyzing further product innovation and expansion into new markets SAN FRANCISCO, June 27, 2024 /PRNewswire/ — Odaseva, the...
Vancouver, Canada’s Highly Anticipated Cultural Destination, Oakridge Park, Announces the “Oakridge Summer Social,” its Special Summer Series for the Community
The Inaugural Oakridge Summer Social Celebrates Canada Day with the Announcement of Latest Canadian Retailers Set to Open at the World-Class Destination in Spring 2025...
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
NEWPORT BEACH, Calif., June 26, 2024 (GLOBE NEWSWIRE) — ELEVAI LABS, INC., (NASDAQ: ELAB) a pioneering force in medical aesthetics, is excited to announce Elevai...
Nxera Pharma Receives US$10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone
Tokyo, Japan and Cambridge, UK, 27 June 2024 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565), announces that it has reached an important R&D milestone...
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Company Announcement Approval based on results from Phase 1/2 EPCORE® NHL-1 study, which demonstrated durable, clinically meaningful treatment responses in patients with challenging-to-treat R/R FL...
Dr. Kevin Cross Is Featured as a Top Doc in Philadelphia
Philadelphia Magazine names Cross Medical Group’s founder as one of the city’s top doctors for 2024 PHILADELPHIA, June 26, 2024 (GLOBE NEWSWIRE) — Each year,...
Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM
Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age...
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is...
Athli App Announces Expansion with the Addition of Three New Trainers
Athli is expanding its fitness offerings with new plans from Bente Strøm, Felicia Lindkvist, and Maisie-Rose Seltzer-Eade BOSTON, June 26, 2024 (GLOBE NEWSWIRE) — Athli,...